ValuentumAd

Official PayPal Seal

Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jul 19, 2017
Novartis’ Clinical Pipeline Continues to Innovate
Image Source: Novartis. We continue to be impressed with the depth of Novartis’ clinical pipeline, which should aid in the company’s acceleration from the revenue cliff experienced as a result of the patent loss of top-selling product Gleevec. We are adding Novartis to the portfolio of the Dividend Growth Newsletter.
Jul 18, 2017
Stocks in the News: Harley-Davidson, Johnson & Johnson, Netflix
Earnings season is picking up. Let’s evaluate a few quarterly reports from some bellwethers.
Jul 14, 2017
Systemic Risk in These Frothy Times
Image shown: Nelson's Syllogism of the Stock Market. Let’s talk about index investing, market valuations, and mention how a few ideas in the portfolio of the Best Ideas Newsletter are doing.
Jul 10, 2017
Stock-Selection Methodology, the Valuentum Buying Index
Image Shown: The size of the circles generally reveals the relative emphasis we place on each investment consideration, while the arrows display the order of our process -- value first then technicals and momentum last.We outline the criteria behind the stock-selection methodology--the Valuentum Buying Index (VBI).
Jul 1, 2017
Malkiel Balks, Yellen Talks
Let’s first address how research in the financial industry is becoming more and more open to combining value and momentum considerations. We’ll also cover a few takeaways from the stress tests and some ‘strong’ talk from Fed Chair Janet Yellen.
Jul 1, 2017
The Financially-Healthiest Dividend Payers Yielding Over 2%
We multiply each firm’s dividend yield by its Dividend Cushion ratio to get this coveted list of the financially-healthiest dividend payers yielding over 2%. Use the download in this article to develop this screen.
Jun 28, 2017
Incyte, Examining Epacadosat's Recent Data
Image shown: Incyte's stock price performance since the beginning of 2014.The need for innovative advances in oncology remains unmet in spite of the entrance of next-generation treatments. We will examine the recent data release from Incyte pertaining to its novel treatment Epacadosat. Incyte hopes it will boost response rates which will greatly expand the number of patients that can be effectively treated. Let’s examine the details of the data release.
Jun 15, 2017
I CARE
Image: The S&P 500 from early 2009 through today, June 15, 2017.
Jun 10, 2017
Glossary of Valuentum Terms
Image Source: Courtney Collison. We define the sections and proprietary metrics found in Valuentum's stock reports.
May 31, 2017
Nevro: An Exciting But Risky Medtech Idea in the Early Stages of Its Growth
Image Source: Nevro. Innovation continues to thrive in the medical field. The rapid aging of the industrialized world’s population bodes well for rising demand. Let’s look at a promising med tech idea, which we believe offers explosive growth in the field of Neuromodulation. It's a risky one though.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.